Harrow Health, Inc. (HROW)
Company Description
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.
In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop.
The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023.
Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Country | United States |
Founded | 1998 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 315 |
CEO | Mark L. Baum J.D. |
Contact Details
Address: 102 Woodmont Blvd, Suite 610 Nashville, Tennessee 37215 United States | |
Phone | 615.733.4731 |
Website | harrowinc.com |
Stock Details
Ticker Symbol | HROW |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001360214 |
CUSIP Number | 415858109 |
ISIN Number | US4158581094 |
Employer ID | 45-0567010 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Mark L. Baum J.D. | Chief Executive Officer and Chairman of the Board |
Andrew R. Boll C.F.A., C.M.A. | Chief Financial Officer and Corporate Secretary |
John P. Saharek MBA | Chief Commercial Officer |
Dr. Dennis E Saadeh Pharm.D. | Chief Scientific Officer |
Jamie Webb | Director of Communications and Investor Relations |
Kim Barratt | Chief of Staff |
Dr. Mark A. Mannebach Ph.D., R.Ph. | Head of Regulatory Affairs and Pharmacovigilance |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 21, 2024 | 8-K | Current Report |
Mar 20, 2024 | 8-K | Current Report |
Mar 19, 2024 | 8-K | Current Report |
Mar 19, 2024 | 10-K | Annual Report |
Feb 15, 2024 | 8-K | Current Report |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 29, 2024 | 8-K | Current Report |
Jan 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |